Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.

Published

Journal Article (Review)

Angiogenesis, the growth of new blood vessels from previously existing vasculature, is a requirement for tumor growth and metastasis. The first US FDA-approved drugs targeting angiogenesis have shown potential in the treatment of malignant gliomas. Immunotherapy as a treatment modality lends itself well to specifically targeting angiogenesis in tumors and may represent a powerful tool in the treatment of malignant gliomas. This review focuses on developments in immunotherapy targeting angiogenesis and tumor-vascular-specific endothelial cells using a variety of immunotherapeutic strategies including monoclonal antibodies and conjugated immunotoxins, as well as cellular, peptide, DNA and dendritic cell vaccines.

Full Text

Duke Authors

Cited Authors

  • Everson, RG; Graner, MW; Gromeier, M; Vredenburgh, JJ; Desjardins, A; Reardon, DA; Friedman, HS; Friedman, AH; Bigner, DD; Sampson, JH

Published Date

  • May 2008

Published In

Volume / Issue

  • 8 / 5

Start / End Page

  • 717 - 732

PubMed ID

  • 18471045

Pubmed Central ID

  • 18471045

Electronic International Standard Serial Number (EISSN)

  • 1744-8328

Digital Object Identifier (DOI)

  • 10.1586/14737140.8.5.717

Language

  • eng

Conference Location

  • England